Graybug Announces Pipeline Expansion, Current Cash Expected to Deliver Three Clinical Readouts in 2023
Phase 2 trial with optimized formulation in wet AMD expected to start in fourth quarter of 2022Phase 1 trial in...
Month: March 2022
Tilray Brands to Announce Third Quarter Fiscal 2022 Financial Results on April 6, 2022
LEAMINGTON, Ontario, March 30, 2022 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray Brands” or the “Company”) (Nasdaq | TSX: TLRY),...
Cognition Therapeutics Reports Year End 2021 Financial Results and Provides Business Update
- Well capitalized from $52 million IPO and $169 million in grant funding -- Established clinical program in Alzheimer’s disease...
CareDx Partners with the European Society for Organ Transplantation to Provide Clinical Evidence Supporting the Use of AlloSeq cfDNA with European Transplant Healthcare Professionals
SOUTH SAN FRANCISCO, Calif., March 30, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on...
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
EMERYVILLE, Calif., March 30, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next...
Replimune Provides New Clinical Data, Broad Program Update and Future Development Strategy for its Tumor-Directed Oncolytic Immunotherapies
RP1 combined with Opdivo® (nivolumab) continues to demonstrate deep and durable responses in patients with melanoma and non-melanoma skin cancers...
Orchard Therapeutics Extends Runway into 2024, Focusing HSC Gene Therapy Platform Exclusively on Severe Neurometabolic Diseases and Research Platform
Libmeldy European launch momentum building with multiple MLD patients treated and strong recognition of value proposition; U.S. BLA filing of...
Trevena to Release Fourth Quarter and Full Year 2021 Financial Results on March 31, 2022
Company to host a Conference Call & Webcast at 8:00 a.m. ETCHESTERBROOK, Pa., March 30, 2022 (GLOBE NEWSWIRE) -- Trevena,...
NERx Biosciences to Present New Data Highlighting Their Pre-clinical Pipeline of Drugs Targeting the DNA Damage Response at American Association For Cancer Research Annual Meeting in April
NERx innovations make leaps towards breast and lung cancer treatmentINDIANAPOLIS, March 30, 2022 (GLOBE NEWSWIRE) -- NERx Biosciences, an oncology...
TELA Bio to Participate in Upcoming Needham & Co. 21st Annual Healthcare Virtual Conference
MALVERN, Pa., March 30, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing...
Confirmation of Appointment of Timothy Scannell to Renalytix Board of Directors
NEW YORK and SALT LAKE CITY, March 30, 2022 (GLOBE NEWSWIRE) -- Renalytix Plc (NASDAQ: RNLX) (LSE: RENX) today announced...
Sol-Gel Technologies Reports Full Year 2021 Financial Results and Corporate Developments
Galderma launched TWYNEO® at the Annual Meetings of the American Academy of Dermatology, March 25-29, 2022 in Boston, MA. TWYNEO...
atai Life Sciences Announces Fourth Quarter and Full Year 2021 Financial Results, Reports on R&D Progress and Highlights Strategic Focus Areas of its Innovative Mental Health Platform
– Highlights included positive Phase 2b data with COMP360 from a ground-breaking treatment resistant depression (TRD) trial, highly encouraging Phase...
Design Therapeutics Completes Dosing in First Patient Cohort of Phase 1 Trial of DT-216 GeneTAC™ Molecule for the Treatment of Friedreich Ataxia
Topline Data from Phase 1 Trial Expected in the Second Half of 2022 DT-216 Granted FDA Fast Track Designation for...
BioNTech Announces Fourth Quarter and Full Year 2021 Financial Results and Corporate Update
Fourth quarter and full year revenues of €5.5 billion1 and €19.0 billion1, respectivelyFull year net income of €10.3 billion and...
Neuronascent Releases Further Positive Results of NNI-362 in A Randomized Phase 1a Trial for Alzheimer’s Disease
ROCKVILLE, Md., March 30, 2022 (GLOBE NEWSWIRE) -- Neuronascent Inc., is a clinical-stage pharmaceutical company discovering and developing novel regenerative...
Ultimovacs to host Investor Days 2022: Meet the Team
Oslo, 30 March 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, will...
Aino Health AB (publ): Aino expands agreement with DHL Supply Chain to include all employees in Sweden
Stockholm, Sweden, March 30: DHL Supply Chain Sweden AB chooses to extend the agreement with Aino Health to the remaining...
Calithera Biosciences, Inc. Prices $10.0 Million Underwritten Public Offering of Common Stock and Warrants to Purchase Common Stock
SOUTH SAN FRANCISCO, Calif., March 30, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical...
Press Release: Availability of the Q1 2022 Memorandum for modelling purposes
Availability of the Q1 2022 Memorandum for modelling purposes Paris, March 30, 2022. Sanofi announced today that its Q1 2022...
